BioCentury
ARTICLE | Company News

Stressgen, Ampersand Ventures deal

May 9, 2005 7:00 AM UTC

SSB completed the previously announced sale of its bioreagents business to Stressgen BioReagents Corp. for C$8 million (US$6.4 million) (see BioCentury, April 18). Stressgen BioReagents was formed by ...